ReviewAntibiotics (Basel, Switzerland)2023
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Risk factors and outcomes associated with difficult-to-treat resistance inEpidemiology and infection · 2026Article
- Article
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- Review
- Clinical characteristics and factors associated with in-hospital mortality in patients withFrontiers in medicine · 2026Article
- What Drives Mortality inMicroorganisms · 2025Article
- Exploring microbial dynamics and metabolomic profiling of isoflavone transformation in black and yellow soybean tempe for sustainable functional foods.Food chemistry. Molecular sciences · 2025Article
- Article
- Epidemiological and Clinical Characteristics ofTropical medicine and infectious disease · 2025Article
- Antimicrobial susceptibility ofAntimicrobial agents and chemotherapy · 2025Article
- Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.BMC infectious diseases · 2025Article
- Novel water-based automated endoscope cleaning process vs conventional manual cleaning for reducing duodenoscope contamination.Endoscopy international open · 2025Article
- Mortality risk factors in patients with bloodstream infections due to multidrug-resistant Gram-negative bacilli.Frontiers in medicine · 2025Article
- Article
- Ventilation Management in a Patient with Ventilation-Perfusion Mismatch in the Early Phase of Lung Injury and during the Recovery.Journal of clinical medicine · 2024Article
- Article
- The Mla system and its role in maintaining outer membrane barrier function inFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MATERIALS: PubMed/MEDLINE and Embase were searched from inception to 30 November 2022. The primary outcome was all-cause mortality. Secondary outcomes included clinical failure, adverse events, and length of stay. A random effects meta-analysis was performed. This study was registered with PROSPERO (CRD42022321893).
resultsTwenty-four studies, all retrospective, were included. A significant difference in terms of overall mortality was observed when comparing as a monotherapy TMP/SMX versus FQs (odds ratio (OR) 1.46, 95% confidence interval (CI) 1.15-1.86, I
conclusionsAgainst SM infections, FQs and, possibly, TDs seem to be reasonable alternative choices to TMP/SMX. Data from clinical trials are urgently needed to better inform therapeutic choices in this setting by also taking into account newer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.